<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01908062</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-CTN-0055</org_study_id>
    <secondary_id>U10DA015815</secondary_id>
    <nct_id>NCT01908062</nct_id>
  </id_info>
  <brief_title>Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study</brief_title>
  <acronym>CHOICES</acronym>
  <official_title>Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn how best to treat substance use disorders in an HIV
      clinic setting. Specifically, the purpose of this pilot study is to learn if extended-release
      naltrexone (XR-NTX) would be a feasible and acceptable treatment for HIV-infected individuals
      with opioid or alcohol use disorders.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Successful Initiation of Treatment Within 4 Weeks of Randomization</measure>
    <time_frame>4 weeks</time_frame>
    <description>Successful induction onto XR-NTX or initiation of treatment as usual within 4 weeks of randomization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Successfully Retained on Pharmacotherapy Treatment at 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>Number of participants who received the maximum possible expected doses of XR-NTX, or the full course of recommended pharmacotherapy treatment for treatment as usual (TAU) arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV Viral Suppression at 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>Plasma HIV viral load of &lt; 200 copies/mL compared with screening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Days of Opioid Use in Past 30 Days</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>Change in 30 day opioid use by Addiction Severity Index (ASI)-lite self-report and Time-Line Follow Back in the final 30 days of the 16 week trial compared to screening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV Care Engagement</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>Change in the proportion of participants prescribed antiretroviral therapy (ART) within 16 weeks following randomization, compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Safety: Change in Liver Enzymes Between Baseline and Week 16</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>Change in liver enzymes between screening and Week 16. AST = Aspartate transaminase ALT = Alanine transaminase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Urine Drug Screen (UDS) Positive for Opioids</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Days of Alcohol Use in Past 30 Days</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>Change in 30 day alcohol use by Addiction Severity Index (ASI)-lite self-report and Time-Line Follow Back in the final 30 days of the 16 week trial compared to screening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Urine Ethyl Glucuronide (EtG) Positive for Alcohol</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Safety: Any Fatal or Non-fatal Overdose Between Baseline and Week 16</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Safety: Precipitated Withdrawal</measure>
    <time_frame>16 weeks</time_frame>
    <description>Proportion of participants assigned to XR-NTX who develop precipitated opioid withdrawal.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Opioid Use Disorder</condition>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Treatment as Usual</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy. HIV-infected patients with alcohol use disorders are typically referred for residential, outpatient, and self-help groups.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended Release Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extended Release Naltrexone</intervention_name>
    <arm_group_label>Extended Release Naltrexone</arm_group_label>
    <other_name>Vivitrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment As usual</intervention_name>
    <arm_group_label>Treatment as Usual</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meet Diagnostic and Statistical Manual (DSM-5) criteria for moderate or severe opioid
             use disorder and/or alcohol use disorder.

          2. Be willing to be randomized to antagonist-based therapy or treatment as usual (TAU)
             for treatment of opioid and/or alcohol use disorders.

          3. Be HIV-infected as defined by history of positive HIV serology or HIV RNA pcr &gt;10,000
             copies/mL).

          4. Be willing to establish ongoing HIV care at community treatment program(CTP) if not
             already receiving ongoing care.

          5. Be willing to initiate antiretroviral therapy (ART) if not already prescribed ART,
             regardless of CD4 count.

          6. Be at least 18 years old.

          7. Be able to provide written informed consent and HIPAA (if applicable) for medical
             record abstraction.

          8. Be able to communicate in English.

          9. If female, be willing to take measures to avoid becoming pregnant.

        Exclusion Criteria:

        Individuals will be excluded from pilot study participation if they:

          -  Have a serious medical, psychiatric or substance use disorder that, in the opinion of
             the study physician, would make study participation hazardous to the participant,
             compromise study findings, or prevent the participant from completing the study.

        Examples include:

          1. Disabling or terminal medical illness (e.g., active opportunistic infection,
             uncompensated heart failure, cirrhosis or end-stage liver disease, acute hepatitis and
             moderate to severe renal impairment) as assessed by medical history, review of
             systems, physical exam and/or laboratory assessments;

               1. Severe, untreated or inadequately treated mental health disorder (e.g., active
                  psychosis, uncontrolled manic-depressive illness) as assessed by history and/or
                  clinical interview;

               2. Current severe benzodiazepine or other depressant or sedative hypnotic use
                  requiring medical detoxification;

               3. Suicidal or homicidal ideation requiring immediate attention.

          2. Have aspartate aminotransferase (AST) or alanine aminotransferase (ALT) liver enzymes
             greater than 5 times upper limit of normal on screening phlebotomy. Results from tests
             conducted within the past 30 days which are abstracted from medical record information
             are acceptable.

          3. Have international normalized ratio (INR) &gt; 1.5 or platelet count &lt;100k. Results from
             tests conducted within the past 30 days which are abstracted from medical record
             information are acceptable.

          4. Have known allergy or sensitivity to naloxone, naltrexone, polylactide-co-glycolide,
             carboxymethylcellulose, or other components of the VivitrolÂ® diluents.

          5. Anticipate undergoing surgery during study participation.

          6. Have chronic pain requiring ongoing pain management with opioid analgesics.

          7. Pending legal action or other reasons that might prevent an individual from completing
             the study.

          8. Currently pregnant or breastfeeding.

          9. Body habitus that, in the judgment of the study physician, precludes safe
             intramuscular injection of XR-NTX, (e.g. excess fat tissue over the buttocks).

         10. Received methadone or buprenorphine maintenance therapy for treatment of opioid
             dependence in the 4 weeks prior to screening.

         11. Have taken an investigational drug in another study within 30 days of study consent.

         12. Have ECG findings that, in the opinion of the study medical clinician would preclude
             safe participation in the study. Results from ECGs conducted within the past 30 days
             which are abstracted from medical record information are acceptable.

         13. Have had treatment with XR-NTX for opioid or alcohol dependence in the 3 months prior
             to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip T Korthuis, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The CORE Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>July 23, 2013</study_first_submitted>
  <study_first_submitted_qc>July 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2013</study_first_posted>
  <results_first_submitted>June 2, 2017</results_first_submitted>
  <results_first_submitted_qc>February 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2019</results_first_posted>
  <last_update_submitted>March 1, 2019</last_update_submitted>
  <last_update_submitted_qc>March 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>P. Todd Korthuis, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Substance related disorders</keyword>
  <keyword>HIV</keyword>
  <keyword>naltrexone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment as Usual</title>
          <description>The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy. HIV-infected patients with alcohol use disorders are typically referred for residential, outpatient, and self-help groups.
Treatment As usual</description>
        </group>
        <group group_id="P2">
          <title>Extended Release Naltrexone</title>
          <description>Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
Extended Release Naltrexone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment as Usual</title>
          <description>The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy. HIV-infected patients with alcohol use disorders are typically referred for residential, outpatient, and self-help groups.
Treatment As usual</description>
        </group>
        <group group_id="B2">
          <title>Extended Release Naltrexone</title>
          <description>Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
Extended Release Naltrexone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="12"/>
                    <measurement group_id="B2" value="47" spread="8.8"/>
                    <measurement group_id="B3" value="46" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Successful Initiation of Treatment Within 4 Weeks of Randomization</title>
        <description>Successful induction onto XR-NTX or initiation of treatment as usual within 4 weeks of randomization.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment as Usual</title>
            <description>The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy. HIV-infected patients with alcohol use disorders are typically referred for residential, outpatient, and self-help groups.
Treatment As usual</description>
          </group>
          <group group_id="O2">
            <title>Extended Release Naltrexone</title>
            <description>Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
Extended Release Naltrexone</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Successful Initiation of Treatment Within 4 Weeks of Randomization</title>
          <description>Successful induction onto XR-NTX or initiation of treatment as usual within 4 weeks of randomization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Successfully Retained on Pharmacotherapy Treatment at 16 Weeks</title>
        <description>Number of participants who received the maximum possible expected doses of XR-NTX, or the full course of recommended pharmacotherapy treatment for treatment as usual (TAU) arm.</description>
        <time_frame>16 weeks</time_frame>
        <population>24 TAU participants, and 17 XR-NTX participants initiated treatment in their respective arms. Treatment retention is calculated only for subjects who have been initiated onto treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment as Usual Pharmacotherapy</title>
            <description>The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy. Pharmacotherapy for TAU participants with alcohol use disorder (AUD) consisted of oral naltrexone, gabapentin, acamprosate, and disulfiram.
Treatment As usual</description>
          </group>
          <group group_id="O2">
            <title>Extended Release Naltrexone</title>
            <description>Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
Extended Release Naltrexone</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Successfully Retained on Pharmacotherapy Treatment at 16 Weeks</title>
          <description>Number of participants who received the maximum possible expected doses of XR-NTX, or the full course of recommended pharmacotherapy treatment for treatment as usual (TAU) arm.</description>
          <population>24 TAU participants, and 17 XR-NTX participants initiated treatment in their respective arms. Treatment retention is calculated only for subjects who have been initiated onto treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV Viral Suppression at 16 Weeks</title>
        <description>Plasma HIV viral load of &lt; 200 copies/mL compared with screening</description>
        <time_frame>16 weeks</time_frame>
        <population>23 TAU participants and 21 XR-NTX participants had a 16-week lab draw for HIV viral load testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment as Usual</title>
            <description>The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy. HIV-infected patients with alcohol use disorders are typically referred for residential, outpatient, and self-help groups.
Treatment As usual</description>
          </group>
          <group group_id="O2">
            <title>Extended Release Naltrexone</title>
            <description>Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
Extended Release Naltrexone</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Viral Suppression at 16 Weeks</title>
          <description>Plasma HIV viral load of &lt; 200 copies/mL compared with screening</description>
          <population>23 TAU participants and 21 XR-NTX participants had a 16-week lab draw for HIV viral load testing.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Days of Opioid Use in Past 30 Days</title>
        <description>Change in 30 day opioid use by Addiction Severity Index (ASI)-lite self-report and Time-Line Follow Back in the final 30 days of the 16 week trial compared to screening.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <population>In both the TAU and XR-NTX groups, reporting results for participants who were retained at 16 weeks and completed necessary study assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment as Usual</title>
            <description>The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy.
Treatment As usual</description>
          </group>
          <group group_id="O2">
            <title>Extended Release Naltrexone</title>
            <description>Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
Extended Release Naltrexone</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Days of Opioid Use in Past 30 Days</title>
          <description>Change in 30 day opioid use by Addiction Severity Index (ASI)-lite self-report and Time-Line Follow Back in the final 30 days of the 16 week trial compared to screening.</description>
          <population>In both the TAU and XR-NTX groups, reporting results for participants who were retained at 16 weeks and completed necessary study assessments.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline mean days opioid use in past 30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="13.14"/>
                    <measurement group_id="O2" value="20.3" spread="12.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 weeks mean days opioid use in past 30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="5.43"/>
                    <measurement group_id="O2" value="7.7" spread="11.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV Care Engagement</title>
        <description>Change in the proportion of participants prescribed antiretroviral therapy (ART) within 16 weeks following randomization, compared to baseline.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment as Usual</title>
            <description>The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy.
Treatment As usual</description>
          </group>
          <group group_id="O2">
            <title>Extended Release Naltrexone</title>
            <description>Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
Extended Release Naltrexone</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Care Engagement</title>
          <description>Change in the proportion of participants prescribed antiretroviral therapy (ART) within 16 weeks following randomization, compared to baseline.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prescribed ART at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prescribed ART at 16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Safety: Change in Liver Enzymes Between Baseline and Week 16</title>
        <description>Change in liver enzymes between screening and Week 16. AST = Aspartate transaminase ALT = Alanine transaminase</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment as Usual</title>
            <description>The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy.
Treatment As usual</description>
          </group>
          <group group_id="O2">
            <title>Extended Release Naltrexone</title>
            <description>Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
Extended Release Naltrexone</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Safety: Change in Liver Enzymes Between Baseline and Week 16</title>
          <description>Change in liver enzymes between screening and Week 16. AST = Aspartate transaminase ALT = Alanine transaminase</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean AST at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" spread="19.4"/>
                    <measurement group_id="O2" value="36.8" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean AST at 16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2" spread="17.6"/>
                    <measurement group_id="O2" value="38.8" spread="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean ALT at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" spread="24.5"/>
                    <measurement group_id="O2" value="35.0" spread="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean ALT at 16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8" spread="18.1"/>
                    <measurement group_id="O2" value="40.1" spread="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Urine Drug Screen (UDS) Positive for Opioids</title>
        <time_frame>Baseline and 16 weeks</time_frame>
        <population>In both the TAU and XR-NTX groups, reporting results for participants who were retained at 16 weeks and completed necessary study assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment as Usual</title>
            <description>The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy.
Treatment As usual</description>
          </group>
          <group group_id="O2">
            <title>Extended Release Naltrexone</title>
            <description>Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
Extended Release Naltrexone</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Urine Drug Screen (UDS) Positive for Opioids</title>
          <population>In both the TAU and XR-NTX groups, reporting results for participants who were retained at 16 weeks and completed necessary study assessments.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline UDS positive for opioids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 weeks UDS positive for opioids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Days of Alcohol Use in Past 30 Days</title>
        <description>Change in 30 day alcohol use by Addiction Severity Index (ASI)-lite self-report and Time-Line Follow Back in the final 30 days of the 16 week trial compared to screening.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <population>In both the TAU and XR-NTX groups, reporting results for participants who were retained at 16 weeks and completed necessary study assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment as Usual</title>
            <description>The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy.
Treatment As usual</description>
          </group>
          <group group_id="O2">
            <title>Extended Release Naltrexone</title>
            <description>Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
Extended Release Naltrexone</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Days of Alcohol Use in Past 30 Days</title>
          <description>Change in 30 day alcohol use by Addiction Severity Index (ASI)-lite self-report and Time-Line Follow Back in the final 30 days of the 16 week trial compared to screening.</description>
          <population>In both the TAU and XR-NTX groups, reporting results for participants who were retained at 16 weeks and completed necessary study assessments.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline mean days alcohol use in past 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="9.95"/>
                    <measurement group_id="O2" value="12.5" spread="11.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 weeks mean days alcohol use in past 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="8.40"/>
                    <measurement group_id="O2" value="2.8" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Urine Ethyl Glucuronide (EtG) Positive for Alcohol</title>
        <time_frame>Baseline and 16 weeks</time_frame>
        <population>In both the TAU and XR-NTX groups, reporting results for participants who were retained at 16 weeks and completed necessary study assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment as Usual</title>
            <description>The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy.
Treatment As usual</description>
          </group>
          <group group_id="O2">
            <title>Extended Release Naltrexone</title>
            <description>Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
Extended Release Naltrexone</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Urine Ethyl Glucuronide (EtG) Positive for Alcohol</title>
          <population>In both the TAU and XR-NTX groups, reporting results for participants who were retained at 16 weeks and completed necessary study assessments.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline EtG positive for alcohol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 weeks EtG positive for alcohol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Safety: Any Fatal or Non-fatal Overdose Between Baseline and Week 16</title>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment as Usual</title>
            <description>The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy.
Treatment As usual</description>
          </group>
          <group group_id="O2">
            <title>Extended Release Naltrexone</title>
            <description>Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
Extended Release Naltrexone</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Safety: Any Fatal or Non-fatal Overdose Between Baseline and Week 16</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nonfatal opioid overdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal opioid overdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Safety: Precipitated Withdrawal</title>
        <description>Proportion of participants assigned to XR-NTX who develop precipitated opioid withdrawal.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Extended Release Naltrexone</title>
            <description>Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
Extended Release Naltrexone</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Safety: Precipitated Withdrawal</title>
          <description>Proportion of participants assigned to XR-NTX who develop precipitated opioid withdrawal.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment as Usual</title>
          <description>The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy. HIV-infected patients with alcohol use disorders are typically referred for residential, outpatient, and self-help groups.
Treatment As usual</description>
        </group>
        <group group_id="E2">
          <title>Extended Release Naltrexone</title>
          <description>Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
Extended Release Naltrexone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache, Migraine</sub_title>
                <counts group_id="E1" events="26" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="25" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Todd Korthuis</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>503-494-8044</phone>
      <email>korthuis@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

